2023-01-202024-01-312024-01-31false14606775CAPSARIS PHARMA LTD2025-01-18falseiso4217:GBPxbrli:pure146067752023-01-20146067752024-01-31146067752023-01-202024-01-31146067752023-01-19146067752023-01-19146067752023-01-192023-01-1914606775bus:SmallEntities2023-01-202024-01-3114606775bus:AuditExempt-NoAccountantsReport2023-01-202024-01-3114606775bus:FullAccounts2023-01-202024-01-3114606775bus:PrivateLimitedCompanyLtd2023-01-202024-01-3114606775core:WithinOneYear2024-01-3114606775core:AfterOneYear2024-01-3114606775core:WithinOneYear2023-01-1914606775core:AfterOneYear2023-01-1914606775core:ShareCapital2024-01-3114606775core:SharePremium2024-01-3114606775core:RevaluationReserve2024-01-3114606775core:OtherReservesSubtotal2024-01-3114606775core:RetainedEarningsAccumulatedLosses2024-01-3114606775core:ShareCapital2023-01-1914606775core:SharePremium2023-01-1914606775core:RevaluationReserve2023-01-1914606775core:OtherReservesSubtotal2023-01-1914606775core:RetainedEarningsAccumulatedLosses2023-01-1914606775core:LandBuildings2024-01-3114606775core:PlantMachinery2024-01-3114606775core:Vehicles2024-01-3114606775core:FurnitureFittings2024-01-3114606775core:OfficeEquipment2024-01-3114606775core:NetGoodwill2024-01-3114606775core:IntangibleAssetsOtherThanGoodwill2024-01-3114606775core:ListedExchangeTraded2024-01-3114606775core:UnlistedNon-exchangeTraded2024-01-3114606775core:LandBuildings2023-01-1914606775core:PlantMachinery2023-01-1914606775core:Vehicles2023-01-1914606775core:FurnitureFittings2023-01-1914606775core:OfficeEquipment2023-01-1914606775core:NetGoodwill2023-01-1914606775core:IntangibleAssetsOtherThanGoodwill2023-01-1914606775core:ListedExchangeTraded2023-01-1914606775core:UnlistedNon-exchangeTraded2023-01-1914606775core:LandBuildings2023-01-202024-01-3114606775core:PlantMachinery2023-01-202024-01-3114606775core:Vehicles2023-01-202024-01-3114606775core:FurnitureFittings2023-01-202024-01-3114606775core:OfficeEquipment2023-01-202024-01-3114606775core:NetGoodwill2023-01-202024-01-3114606775core:IntangibleAssetsOtherThanGoodwill2023-01-202024-01-3114606775core:ListedExchangeTraded2023-01-202024-01-3114606775core:UnlistedNon-exchangeTraded2023-01-202024-01-3114606775core:MoreThanFiveYears2023-01-202024-01-3114606775core:Non-currentFinancialInstruments2024-01-3114606775core:Non-currentFinancialInstruments2023-01-1914606775dpl:CostSales2023-01-202024-01-3114606775dpl:DistributionCosts2023-01-202024-01-3114606775core:LandBuildings2023-01-202024-01-3114606775core:PlantMachinery2023-01-202024-01-3114606775core:Vehicles2023-01-202024-01-3114606775core:FurnitureFittings2023-01-202024-01-3114606775core:OfficeEquipment2023-01-202024-01-3114606775dpl:AdministrativeExpenses2023-01-202024-01-3114606775core:NetGoodwill2023-01-202024-01-3114606775core:IntangibleAssetsOtherThanGoodwill2023-01-202024-01-3114606775dpl:GroupUndertakings2023-01-202024-01-3114606775dpl:ParticipatingInterests2023-01-202024-01-3114606775dpl:GroupUndertakingscore:ListedExchangeTraded2023-01-202024-01-3114606775core:ListedExchangeTraded2023-01-202024-01-3114606775dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-01-202024-01-3114606775core:UnlistedNon-exchangeTraded2023-01-202024-01-3114606775dpl:CostSales2023-01-192023-01-1914606775dpl:DistributionCosts2023-01-192023-01-1914606775core:LandBuildings2023-01-192023-01-1914606775core:PlantMachinery2023-01-192023-01-1914606775core:Vehicles2023-01-192023-01-1914606775core:FurnitureFittings2023-01-192023-01-1914606775core:OfficeEquipment2023-01-192023-01-1914606775dpl:AdministrativeExpenses2023-01-192023-01-1914606775core:NetGoodwill2023-01-192023-01-1914606775core:IntangibleAssetsOtherThanGoodwill2023-01-192023-01-1914606775dpl:GroupUndertakings2023-01-192023-01-1914606775dpl:ParticipatingInterests2023-01-192023-01-1914606775dpl:GroupUndertakingscore:ListedExchangeTraded2023-01-192023-01-1914606775core:ListedExchangeTraded2023-01-192023-01-1914606775dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-01-192023-01-1914606775core:UnlistedNon-exchangeTraded2023-01-192023-01-1914606775core:NetGoodwill2024-01-3114606775core:IntangibleAssetsOtherThanGoodwill2024-01-3114606775core:LandBuildings2024-01-3114606775core:PlantMachinery2024-01-3114606775core:Vehicles2024-01-3114606775core:FurnitureFittings2024-01-3114606775core:OfficeEquipment2024-01-3114606775core:AfterOneYear2024-01-3114606775core:WithinOneYear2024-01-3114606775core:ListedExchangeTraded2024-01-3114606775core:UnlistedNon-exchangeTraded2024-01-3114606775core:ShareCapital2024-01-3114606775core:SharePremium2024-01-3114606775core:RevaluationReserve2024-01-3114606775core:OtherReservesSubtotal2024-01-3114606775core:RetainedEarningsAccumulatedLosses2024-01-3114606775core:NetGoodwill2023-01-1914606775core:IntangibleAssetsOtherThanGoodwill2023-01-1914606775core:LandBuildings2023-01-1914606775core:PlantMachinery2023-01-1914606775core:Vehicles2023-01-1914606775core:FurnitureFittings2023-01-1914606775core:OfficeEquipment2023-01-1914606775core:AfterOneYear2023-01-1914606775core:WithinOneYear2023-01-1914606775core:ListedExchangeTraded2023-01-1914606775core:UnlistedNon-exchangeTraded2023-01-1914606775core:ShareCapital2023-01-1914606775core:SharePremium2023-01-1914606775core:RevaluationReserve2023-01-1914606775core:OtherReservesSubtotal2023-01-1914606775core:RetainedEarningsAccumulatedLosses2023-01-1914606775core:NetGoodwill2023-01-1914606775core:IntangibleAssetsOtherThanGoodwill2023-01-1914606775core:LandBuildings2023-01-1914606775core:PlantMachinery2023-01-1914606775core:Vehicles2023-01-1914606775core:FurnitureFittings2023-01-1914606775core:OfficeEquipment2023-01-1914606775core:AfterOneYear2023-01-1914606775core:WithinOneYear2023-01-1914606775core:ListedExchangeTraded2023-01-1914606775core:UnlistedNon-exchangeTraded2023-01-1914606775core:ShareCapital2023-01-1914606775core:SharePremium2023-01-1914606775core:RevaluationReserve2023-01-1914606775core:OtherReservesSubtotal2023-01-1914606775core:RetainedEarningsAccumulatedLosses2023-01-1914606775core:AfterOneYear2023-01-202024-01-3114606775core:WithinOneYear2023-01-202024-01-3114606775core:Non-currentFinancialInstrumentscore:CostValuation2023-01-202024-01-3114606775core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-01-202024-01-3114606775core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-01-202024-01-3114606775core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-01-202024-01-3114606775core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-01-202024-01-3114606775core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-01-202024-01-3114606775core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-01-202024-01-3114606775core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-01-202024-01-3114606775core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-01-202024-01-3114606775core:Non-currentFinancialInstrumentscore:CostValuation2024-01-3114606775core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-01-3114606775core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-01-3114606775core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-01-3114606775core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-01-3114606775core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-01-3114606775core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-01-3114606775core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-01-3114606775core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-01-3114606775core:Non-currentFinancialInstrumentscore:CostValuation2023-01-1914606775core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-01-1914606775core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-01-1914606775core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-01-1914606775core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-01-1914606775core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-01-1914606775core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-01-1914606775core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-01-1914606775core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-01-1914606775bus:Director12023-01-202024-01-3114606775bus:Director22023-01-202024-01-3114606775bus:Director32023-01-202024-01-3114606775bus:Director42023-01-202024-01-31

CAPSARIS PHARMA LTD

Registered Number
14606775
(England and Wales)

Unaudited Financial Statements for the Period ended
31 January 2024

CAPSARIS PHARMA LTD
Company Information
for the period from 20 January 2023 to 31 January 2024

Directors

ANYAMENE, Ifesinachi Chidinma
ANYAMENE, Okechukwu Joseph
NZE, Ebele
NZE, Ikenna Uzodimma

Registered Address

64 Windham Avenue New Addington
Croydon
CR0 0HW

Registered Number

14606775 (England and Wales)
CAPSARIS PHARMA LTD
Balance Sheet as at
31 January 2024

Notes

2024

£

£

Fixed assets
Intangible assets3334,078
Tangible assets411,224
345,302
Current assets
Stocks545,601
Debtors6112,581
Cash at bank and on hand67,547
225,729
Creditors amounts falling due within one year7(558,799)
Net current assets (liabilities)(333,070)
Total assets less current liabilities12,232
Net assets12,232
Capital and reserves
Called up share capital100
Profit and loss account12,132
Shareholders' funds12,232
The financial statements were approved and authorised for issue by the Board of Directors on 18 January 2025, and are signed on its behalf by:
NZE, Ikenna Uzodimma
Director
Registered Company No. 14606775
CAPSARIS PHARMA LTD
Notes to the Financial Statements
for the period ended 31 January 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Intangible assets
Intangible assets are stated at cost less accumulated amortisation and accumulated impairment losses. The assets are reviewed for impairment if the above factors indicate that the carrying amount may be impaired. Amortisation is included in 'administrative expenses' in the profit and loss account.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Reducing balance (%)
Plant and machinery15
Stocks and work in progress
Stock is valued at the lower of cost and estimated selling price less costs to complete and sell. The cost methodology employed by the entity is the first-in first-out method. Estimated selling price less costs to complete and sell are derived from the selling price which the goods would fetch in an open market transaction with established customers less the costs expected to be incurred to enable the sale to complete. Provision is made for slow-moving and obsolete items of stock. Such provisions are recognised in profit or loss. Work in progress is valued using the percentage of completion method and values are calculated using the lower of cost and estimated selling price less costs to complete and sell. When stocks are sold, the carrying amount of those stocks is recognised as an expense within cost of sales. This takes place in the same period that the associated revenue is recognised.
2.Average number of employees

2024
Average number of employees during the year3
3.Intangible assets

Goodwill

Total

££
Cost or valuation
Additions354,773354,773
At 31 January 24354,773354,773
Amortisation and impairment
Charge for year20,69520,695
At 31 January 2420,69520,695
Net book value
At 31 January 24334,078334,078
At 19 January 23--
4.Tangible fixed assets

Plant & machinery

Total

££
Cost or valuation
Additions12,30012,300
At 31 January 2412,30012,300
Depreciation and impairment
Charge for year1,0761,076
At 31 January 241,0761,076
Net book value
At 31 January 2411,22411,224
At 19 January 23--
5.Stocks

2024

£
Finished goods45,601
Total45,601
6.Debtors: amounts due within one year

2024

£
Trade debtors / trade receivables85,563
Other debtors27,018
Total112,581
7.Creditors: amounts due within one year

2024

£
Trade creditors / trade payables71,523
Amounts owed to related parties431,787
Taxation and social security6,345
Payments received on account40,854
Accrued liabilities and deferred income8,290
Total558,799
8.Related party transactions
At the yearend, the company owed £212,378 (2023: NIL) and £209,409 (2023: NIL) to Capsaris Holdings UK Limited and Capsaris (UK) Limited respectively. The companies are related as Mr. I U Nze, Mr. O J Anyamene, Mrs. I C Anyamene and Mrs E NZE are also the directors of these companies.